Press release

Mar 06, 2019

Hansa Biopharma to Present at the Cowen 39th Annual Health Care Conference

Lund, Sweden, March 6, 2019 – Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that Søren Tulstrup, President and CEO of Hansa Biopharma, will present at the Cowen 39th Annual Health Care Conference on Wednesday, March 13, 2019 at 9:20AM ET/ 3:20PM CET. The conference will be held at the Boston Marriott Copley Place in Boston, MA. 

A live webcast will be available on the Events & Webcast page of the Company's website, www.hansabiopharma.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation. 

The information was submitted for publication, through the agency of the contact person set out below at 08:00am CET on March 6, 2019.  

About Hansa Biopharma
Hansa Biopharma AB (NASDAQ Stockholm:HNSA) is harnessing its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions and cancer. The Company’s lead product, imlifidase, is a unique antibody-degrading enzyme in late-stage clinical development to enable kidney transplantation in highly sensitized patients, with additional clinical studies in acute autoimmune indications. Hansa’s research and development program is advancing the next generation of the Company’s technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden.